Department of Molecular Biology and Biochemistry, Francisco J. Ayala School of Biological Sciences, University of California-Irvine, Irvine, California, USA.
UCLA AIDS Institute, Los Angeles, California, USA.
J Virol. 2019 Sep 30;93(20). doi: 10.1128/JVI.00364-19. Print 2019 Oct 15.
The HIV/AIDS pandemic remains an important threat to human health. We have recently demonstrated that a novel microRNA (miR), miR-128, represses retrotransposon long interspaced element 1 (L1) by a dual mechanism, namely, by directly targeting the coding region of the L1 RNA and by repressing a required nuclear import factor (TNPO1). We have further determined that miR-128 represses the expression of all three TNPO proteins (transportins TNPO1, TNPO2, and TNPO3). Here, we establish that miR-128 also influences HIV-1 replication by repressing TNPO3, a factor that regulates HIV-1 nuclear import and viral; replication of TNPO3 is well established to regulate HIV-1 nuclear import and viral replication. Here, we report that type I interferon (IFN)-inducible miR-128 directly targets two sites in the TNPO3 mRNA, significantly downregulating TNPO3 mRNA and protein expression levels. Challenging miR-modulated Jurkat cells or primary CD4 T-cells with wild-type (WT), replication-competent HIV-1 demonstrated that miR-128 reduces viral replication and delays spreading of infection. Manipulation of miR-128 levels in HIV-1 target cell lines and in primary CD4 T-cells by overexpression or knockdown showed that reduction of TNPO3 levels by miR-128 significantly affects HIV-1 replication but not murine leukemia virus (MLV) infection and that miR-128 modulation of HIV-1 replication is reduced with TNPO3-independent HIV-1 virus, suggesting that miR-128-indued TNPO3 repression contributes to the inhibition of HIV-1 replication. Finally, we determine that anti-miR-128 partly neutralizes the IFN-mediated block of HIV-1. Thus, we have established a novel role of miR-128 in antiviral defense in human cells, namely inhibiting HIV-1 replication by altering the cellular milieu through targeting factors that include TNPO3. HIV-1 is the causative agent of AIDS. During HIV-1 infection, type I interferons (IFNs) are induced, and their effectors limit HIV-1 replication at multiple steps in its life cycle. However, the cellular targets of INFs are still largely unknown. In this study, we identified the interferon-inducible microRNA (miR) miR-128, a novel antiviral mediator that suppresses the expression of the host gene TNPO3, which is known to modulate HIV-1 replication. Notably, we observe that anti-miR-128 partly neutralizes the IFN-mediated block of HIV-1. Elucidation of the mechanisms through which miR-128 impairs HIV-1 replication may provide novel candidates for the development of therapeutic interventions.
艾滋病仍然是人类健康的一个重要威胁。我们最近证明,一种新型 microRNA(miR),miR-128,通过双重机制抑制逆转录转座子长间隔元件 1(L1),即直接靶向 L1 RNA 的编码区,并抑制必需的核输入因子(TNPO1)。我们进一步确定 miR-128 还通过抑制 TNPO3 来抑制所有三种 TNPO 蛋白(TNPO1、TNPO2 和 TNPO3)的表达。在这里,我们建立了 miR-128 还通过抑制 TNPO3 来影响 HIV-1 的复制,TNPO3 是调节 HIV-1 核输入和病毒的因素;TNPO3 的复制已被证实可调节 HIV-1 的核输入和病毒复制。在这里,我们报告说,I 型干扰素(IFN)诱导的 miR-128 直接靶向 TNPO3 mRNA 的两个位点,显著下调 TNPO3 mRNA 和蛋白表达水平。用野生型(WT)、具有复制能力的 HIV-1 挑战 miR 调节的 Jurkat 细胞或原代 CD4 T 细胞表明,miR-128 降低病毒复制并延迟感染的传播。通过过表达或敲低 HIV-1 靶细胞系和原代 CD4 T 细胞中的 miR-128 水平表明,miR-128 下调 TNPO3 水平显著影响 HIV-1 复制,但不影响鼠白血病病毒(MLV)感染,并且 miR-128 对 HIV-1 复制的调节作用降低与 TNPO3 无关的 HIV-1 病毒,表明 miR-128 诱导的 TNPO3 抑制有助于抑制 HIV-1 复制。最后,我们确定抗 miR-128 部分中和了 IFN 介导的 HIV-1 阻断。因此,我们在人类细胞的抗病毒防御中确立了 miR-128 的新作用,即通过改变包括 TNPO3 在内的细胞因子来抑制 HIV-1 复制。HIV-1 是艾滋病的致病因子。在 HIV-1 感染期间,诱导 I 型干扰素(IFN),其效应物在其生命周期的多个步骤中限制 HIV-1 的复制。然而,INFs 的细胞靶标在很大程度上仍然未知。在这项研究中,我们鉴定了干扰素诱导的 microRNA(miR)miR-128,这是一种新型抗病毒介质,可抑制宿主基因 TNPO3 的表达,已知 TNPO3 可调节 HIV-1 复制。值得注意的是,我们观察到抗 miR-128 部分中和了 IFN 介导的 HIV-1 阻断。阐明 miR-128 损害 HIV-1 复制的机制可能为开发治疗干预措施提供新的候选药物。